$440,000 of EMERGENT BIOSOLUTIONS INC lobbying was just disclosed, from Q2 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"- Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act - Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY25 and FY26 - Opioid crisis legislation, naloxone access and awareness - State opioid response (SOR) Grant funding FY25 and FY26 - Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY25 and FY26 - Tribal Opioid Response Grant funding for FY26 - NDAA for Fiscal Year 2025 and Fiscal Year 2026 - provisions related to biological and chemical defense and access to naloxone - H.R.1968, the Full-Year Continuing Appropriations and Extensions Act, 2025 - Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act - Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY25 and FY26 - Opioid crisis legislation, naloxone access and awareness - State opioid response (SOR) Grant funding FY25 and FY26 - Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY25 and FY26 - Tribal Opioid Response Grant funding for FY26 - NDAA for Fiscal Year 2025 and Fiscal Year 2026 - provisions related to biological and chemical defense and access to naloxone - H.R.1968, the Full-Year Continuing Appropriations and Extensions Act, 2025 - Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act - Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY25 and FY26 - Opioid crisis legislation, naloxone access and awareness - State opioid response (SOR) Grant funding FY25 and FY26 - Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY25 and FY26 - Tribal Opioid Response Grant funding for FY26 - NDAA for Fiscal Year 2025 and Fiscal Year 2026 - provisions related to biological and chemical defense and access to naloxone - H.R.1968, the Full-Year Continuing Appropriations and Extensions Act, 2025 - Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act - Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY25 and FY26 - Opioid crisis legislation, naloxone access and awareness - State opioid response (SOR) Grant funding FY25 and FY26 - Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY25 and FY26 - Tribal Opioid Response Grant funding for FY26 - NDAA for Fiscal Year 2025 and Fiscal Year 2026 - provisions related to biological and chemical defense and access to naloxone - H.R.1968, the Full-Year Continuing Appropriations and Extensions Act, 2025"
You can find more data on corporate lobbying on Quiver Quantitative.
EBS Insider Trading Activity
EBS insiders have traded $EBS stock on the open market 3 times in the past 6 months. Of those trades, 0 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $EBS stock by insiders over the last 6 months:
- NEAL FRANKLIN FOWLER sold 35,000 shares for an estimated $204,050
- KATHRYN C ZOON sold 10,000 shares for an estimated $57,300
- KEITH KATKIN sold 7,844 shares for an estimated $49,417
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
EBS Hedge Fund Activity
We have seen 82 institutional investors add shares of EBS stock to their portfolio, and 72 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MILLENNIUM MANAGEMENT LLC added 1,020,582 shares (+68.9%) to their portfolio in Q1 2025, for an estimated $4,960,028
- LSV ASSET MANAGEMENT added 809,591 shares (+3748.1%) to their portfolio in Q1 2025, for an estimated $3,934,612
- INVESCO LTD. removed 791,948 shares (-51.4%) from their portfolio in Q1 2025, for an estimated $3,848,867
- CHARLES SCHWAB INVESTMENT MANAGEMENT INC removed 706,959 shares (-54.8%) from their portfolio in Q1 2025, for an estimated $3,435,820
- ACADIAN ASSET MANAGEMENT LLC added 631,794 shares (+313.5%) to their portfolio in Q1 2025, for an estimated $3,070,518
- DIMENSIONAL FUND ADVISORS LP added 492,579 shares (+44.6%) to their portfolio in Q1 2025, for an estimated $2,393,933
- TWO SIGMA INVESTMENTS, LP removed 449,966 shares (-53.1%) from their portfolio in Q1 2025, for an estimated $2,186,834
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
EBS Analyst Ratings
Wall Street analysts have issued reports on $EBS in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 04/01/2025
To track analyst ratings and price targets for EBS, check out Quiver Quantitative's $EBS forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
